Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
about
The proximal signaling network of the BCR-ABL1 oncogene shows a modular organizationProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaChemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaPh+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cellsStem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic LeukemiaMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036Secondary mutations as mediators of resistance to targeted therapy in leukemiaSrc activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinasesSurvival regulation of leukemia stem cellsHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsLSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cellsATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistanceThe Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic MalignanciesMapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy.The antibiotic potential of prokaryotic IMP dehydrogenase inhibitorsTransient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiationDasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorPTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in miceGlobal phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patientsBCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cellsLoss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells.Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo.Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cellsTyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients.Δ12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice
P2860
Q24294830-7B1CE7DF-15CD-4A81-A06E-687D8FE86883Q24607114-6226F322-BF5C-4F39-BA79-D53E8A29362FQ24622397-54E610C7-B704-414C-9C37-1FC1C2F103D7Q24650730-C0F842DB-B6C9-489C-8E71-03A40298BD3FQ26799954-2E48C979-291C-41D9-B43C-559552D7DEE3Q26828528-84F77F2E-8A49-4165-9FF7-4D439467E539Q26849792-33E09AE3-F290-4690-B077-20B0EF269486Q27025242-661FA9A3-6A29-47A8-BA48-BAD57C1DE798Q27028181-B47D25F1-8075-4E62-845A-49F1081C0FB0Q27667482-D680D28D-AE33-4D30-8CD3-141790CF77A1Q28087213-CB565092-3C60-462D-8C43-B162F48BCCF0Q28248761-0DE20956-9287-433A-9579-B9D471EACE09Q28271278-90A01EB4-661B-42F9-9D0C-5E7D098D131DQ28393898-FFA125DF-E027-4BA6-B269-D891365D52EBQ28484079-3BA84EFB-CD8D-4EB3-86F2-444066D7A915Q28540033-8B0A043E-450B-427A-AEE3-1457E9BA8AD1Q28551057-9FC9F1AD-ABF4-45C7-8E7B-1E23E93BD8ECQ30009317-1F4B91C4-BFD6-4618-948C-ED7848080AE4Q30356398-0C6A1305-B3F6-4E5C-9FF6-596C1A39E4BCQ33369693-EE2C5011-3E5A-467C-BC21-98B950B4296CQ33384766-6A41835A-B80F-4C53-B51D-7B2C1C068CE1Q33442587-E17B965E-6547-4B31-ACDA-F194FCBCC93CQ33597663-011381E6-F6A9-4E7F-90E2-12C5CAF6C1AAQ33608760-A1CEA9EA-7108-48DA-92BB-E686655BDD4EQ33753325-D62B5818-8253-4051-929C-CF6AB4ECD601Q33770326-66F7AE37-0CC7-4D73-87A8-5A04AF8D741EQ33798573-D7A49746-3A2F-4251-93E9-11BEABBC54DFQ33806036-7AED0C7A-A2D8-4225-8D43-3BDFF861E651Q33921399-43CF7565-2949-45B2-B4D9-5DB6E5A16889Q33947776-4507F1C3-9E6F-46D8-8E45-E4E24E46D169Q33988398-48E8BFE6-933B-43B1-9CF7-48D156E68EDEQ34062313-FC1DAD90-479E-47E3-9DB0-940E2CA5E97EQ34087767-30B9473B-3BDA-4B90-A1AD-BA99E4343543Q34117463-D163A3AF-2DA6-4B16-90B0-151792FDA5B2Q34157874-03D90B88-4DC6-4B28-9FFE-2D9FA6D860D1Q34251497-233614EA-D7E3-449B-943E-CEB3D0BBACA9Q34272962-CF3F922F-2A0D-4F1C-A46B-9915F2F00CF7Q34335004-2BA5C5FF-3CC5-4D6C-9F3F-8EFCE4211E7CQ34547402-8E83DAC1-8137-4842-8C07-4B1DE11C4109Q34632798-C7EB2B64-3B56-46F0-A69D-D537477410BF
P2860
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.
@ast
Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.
@en
type
label
Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.
@ast
Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.
@en
prefLabel
Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.
@ast
Targeting multiple kinase path ...... tment of Ph+ leukemia in mice.
@en
P2093
P2860
P356
P1476
Targeting multiple kinase path ...... atment of Ph+ leukemia in mice
@en
P2093
Francis Y Lee
Roberto Weinmann
Sarah Swerdlow
Shaoguang Li
Theodore M Duffy
P2860
P304
16870-16875
P356
10.1073/PNAS.0606509103
P407
P50
P577
2006-10-31T00:00:00Z